<DOC>
	<DOCNO>NCT01445821</DOCNO>
	<brief_summary>ASSIST I first randomize trial patient scleroderma slow disease progression rather actually reverse . It first treatment ever demonstrate reversal lung disease scleroderma improvement FVC , total lung capacity ( TLC ) , high-resolution compute tomography ( HRCT ) , QOL . We , therefore , purpose compare ASSIST I condition regimen cyclophosphamide rATG less intense regimen rATG/cyclophosphamide/Fludarabine . In new regimen cyclophosphamide dose decrease 120mg/kg ( 60mg/kg/day x 2 ) compare 200mg/kg ( 50mg/kg/day ) standard regimen . The low dose cyclophosphamide less cardiotoxic . This study determine less cardiotoxic regimen safer standard regimen effective standard regimen .</brief_summary>
	<brief_title>Autologous Stem Cell Systemic Sclerosis Immune Suppression Trial</brief_title>
	<detailed_description>Mobilization . For patient arm undergo hematopoietic stem cell transplantation , peripheral blood stem cell ( PBSC ) mobilize cyclophosphamide ( 2 g/m2 ) follow 5-10 mcg/kg subcutaneous filgrastrim daily day 5 completion apheresis . Mobilized hematopoietic stem cell ( HSC ) collect apheresis day 10 cryopreserved without selection manipulation . There interval least 17 day mobilization PBSC start condition regimen . Control arm . The control arm conditioning regimen use ASSIST study . The condition regimen 200 mg/kg intravenous cyclophosphamide give 4 equal fraction day -5 -2 intravenous mesna . Rabbit anti-thymocyte globulin ( rATG ) ( Thymoglobulin® ) dose 0.5 mg/kg day-5 1.5 mg/kg day-4 thru day -1 . Methylprednisolone 1000 mg use infuse intravenously dose rATG . PBSC infuse intravenously day 0 . Filgrastrim 5-10 mcg/kg start day + 5 continued neutrophil engraftment . Cytoxan rATG/Fludarabine arm The conditioning regimen 120 mg/kg intravenous cyclophosphamide give 2 equal fraction day -3 -2 intravenous mesna . Rabbit anti-thymocyte globulin ( rATG ) ( Thymoglobulin® ) dose 0.5 mg/kg day-5 1.5 mg/kg day-4 thru day -1 . Fludarabine 30 g/m2 give IV day -5 , -4 , -3 . Methylprednisolone 1000 mg use infuse intravenously dose rATG . PBSC infuse intravenously day 0 . Filgrastrim 5-10 mcg/kg start day + 5 continued neutrophil engraftment .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Scleroderma , Systemic</mesh_term>
	<mesh_term>Scleroderma , Diffuse</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>1 . Age 17 60 year old time pretransplant evaluation 2 . An establish diagnosis scleroderma 3 . Diffuse cutaneous scleroderma involvement proximal elbow knee Rodnan score ( see Appendix V ) &gt; 14 AND Scleroderma one following : 1 . DLCO &lt; 80 % predict decrease lung function ( DLCO , DLCO/VA FVC ) 10 % 12 month . 2 . Pulmonary fibrosis alveolitis CT scan chest Xray ( CXR ) ( ground glass appearance alveolitis ) . 3 . Abnormal EKG [ nonspecific STT ( pattern electrocardiogram ) wave abnormality , low QRS ( pattern see electrocardiogram indicate pulse heart beat duration ) voltage , ventricular hypertrophy ] , pericardial effusion pericardial enhancement MRI 4 . Gastrointestinal tract involvement confirm radiological study . Radiologic finding scleroderma small bowel radiograph show thickened fold dilate loop , segmentation , flocculation +/ diverticulae , pseudodiverticulae . A hidebound appearance due valvulae pack i.e . dilate crowd circular fold may present . GI involvement may also confirm Dxylose malabsorption , patulous esophagus HRCT , esophageal manometry . OR 4 . As publish NEJM ( New England Journal Medicine ) , 2006 , 345:25 26552709 . Limited diffuse Systemic Sclerosis ( SSCL ) lung involvement define active alveolitis Bronchoalveolar Lavage ( BAL ) groundglass opacity CT , DLCO &lt; 80 % predict decrease lung function ( DLCO/VA , DLCO , FVC ) 10 % last 12 month . 1 . Significant end organ damage : 1 . Left Ventricular Function ( LVEF ) &lt; 40 % echocardiogram . 2 . Untreated lifethreatening arrhythmia . 3 . Active ischemic heart disease heart failure . 4 . Endstage lung disease characterize TLC &lt; 45 % predict value , DLCO hemoglobin correct &lt; 30 % predict . 5 . Pulmonary arterial hypertension define right heart catheterization : 1. rest Mean Pulmonary Artery Pressure ( mPAP ) &gt; 25 mmHg ; 2. mPAP &gt; 30 mmHg follow 5001000 ml normal saline bolus ; 3. pulmonary vascular resistance ( PVR ) &gt; 240 dynes*s/cm5 ( &gt; 3 Wood unit ) ; 4. decrease cardiac output fluid challenge ( 500 1000 cc Normal Saline ( NS ) 10 minute ) If fluid challenge do right atrial ( RA ) pressure &gt; 12mm Hg pulmonary capillary wedge pressure ( PCWP ) &gt; 15 Hg rest must stop due safety concern , patient exclude candidate . 6 . Serum creatinine &gt; 1.4 mg/dl . 7 . Liver cirrhosis , transaminases &gt; 3x normal limit bilirubin &gt; 2.0 unless due Gilbert 's disease . 8 . Pericardial effusion &gt; 1 cm cardiac MRI unless successful pericardiocentesis perform 9 . Occult clinical constrictive pericarditis 10 . On echocardiogram tricuspid annular peak systolic excursion ( TAPSE ) ≤ 1.8 cm , grade II bad RV Left Ventricular ( LV ) diastolic dysfunction 11 . On cardiac MRI , diastolic septal bounce diastolic septal flattering ( Dsign ) , diffuse myocardial gadolinium enhancement , diffuse hypokinesis ( patchy late gadolinium myocardial enhancement exclusion criterion ) 12 . Ventricular tachycardia ( sustain nonsustained , multifocal unifocal ) EKG 24 hour Holter 2 . HIV positive . 3 . Uncontrolled diabetes mellitus illness opinion investigator would jeopardize ability patient tolerate aggressive treatment . 4 . Prior history malignancy 5 . Positive pregnancy test , inability unable pursue effective mean birth control , failure willingly accept comprehend irreversible sterility side effect therapy . 6 . Psychiatric illness mental deficiency make compliance treatment inform consent impossible . 7 . Inability give inform consent . 8 . Major hematological abnormality platelet count &lt; 100,000/ul absolute neutrophil count ( ANC ) &lt; 1000/ul . 9 . Hepatitis B C positive</criteria>
	<gender>All</gender>
	<minimum_age>17 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>systemic scleroderma</keyword>
	<keyword>autologous stem cell transplantation</keyword>
</DOC>